0.9205

3.11% -0.0295

Palatin Technologies Inc. (PTN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Palatin Technologies Inc. stock is traded at $0.9205, with a volume of 459.60K. It is down -3.11% in the last 24 hours and down -3.60% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Previous Close:

$0.95

Open:

$0.95

24h Volume:

459.60K

Relative Volume:

0.56

Market Cap:

$23.94M

Revenue:

$7.10M

Net Income/Loss:

$-31.59M

P/E Ratio:

-0.3527

EPS:

-2.61

Net Cash Flow:

$-26.75M

1W Performance:

-10.63%

1M Performance:

-3.60%

6M Performance:

-40.23%

1Y Performance:

-70.59%

1-Day Range:

$0.90

$0.99

1-Week Range:

$0.90

$1.0596

52-Week Range:

$0.68

$3.9929

Palatin Technologies Inc. Stock (PTN) Company Profile

Name

Palatin Technologies Inc.

Sector

Healthcare (1167)

Industry

Biotechnology (674)

Phone

609-495-2200

Address

Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ

Employee

Twitter

@PalatinTech

Next Earnings Date

2024-11-12

Latest SEC Filings

PTN's Discussions on Twitter

Compare PTN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTN Palatin Technologies Inc.	0.9205	23.94M	7.10M	-31.59M	-26.75M	-2.61
VRTX Vertex Pharmaceuticals Inc	480.35	123.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	723.47	79.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.94	37.97B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.20	31.74B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.70	27.71B	3.32B	-860.46M	-1.04B	-8.32

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy
Jan-12-15	Reiterated	ROTH Capital	Buy
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy

Palatin Technologies Inc. Stock (PTN) Latest News

Feb 24, 2025

Palatin Awaits Data Release From Phase 2 Trial Of Bremelanotide-Tirzepatide Combo In Weight Loss - RTTNews

Feb 24, 2025

Feb 20, 2025

Palatin secures $4.7 million in stock and warrant sale By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 16, 2025

HC Wainwright Cuts Palatin Technologies (NYSEAMERICAN:PTN) Price Target to $7.00 - Armenian Reporter

Feb 16, 2025

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update - br.ADVFN.com

Feb 16, 2025

Feb 15, 2025

HC Wainwright Issues Pessimistic Forecast for Palatin Technologies (NYSEAMERICAN:PTN) Stock Price - Defense World

Feb 15, 2025

Feb 14, 2025

Palatin Technologies, Inc. (AMEX:PTN) Q2 2025 Earnings Call Transcript - Insider Monkey

Feb 14, 2025